Navigation Links
Cambrex Regains Compliance With Revised NYSE Listing Standards
Date:6/4/2009

EAST RUTHERFORD, N.J., June 4 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced today that it has received notice from the New York Stock Exchange ("NYSE") informing the Company that it is in compliance with the revised NYSE continued listing standards. As announced by the Company on April 14, 2009, the Company had failed to meet the NYSE continued listing standards because its average market capitalization over a consecutive 30-day period and total shareholders' equity had each fallen below the NYSE $75 million threshold. The Securities Exchange Commission recently approved a pilot program effective through October 31, 2009, whereby the NYSE threshold is lowered to $50 million. The Company is in compliance with these new listing standards. The NYSE has indicated that it expects to file a subsequent rule filing prior to October 31, 2009 that is intended to make this change to the listing standard permanent.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including active pharmaceutical ingredients ("API"), advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. For more information, please visit www.cambrex.com.


'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
2. Cambrex Signs Agreement To Acquire ProSyntest AS
3. Cambrex Reports Fourth Quarter and Full-Year 2007 Results
4. Cambrex Customer Announced Recall
5. Cambrex to Announce First Quarter 2008 Financial Results on May 1, 2008
6. Cambrex Presentation at The JPMorgan Healthcare Conference to be Webcast
7. Skinvisible and Cambrex Enter Into Agreement to Develop Acne Products
8. Cambrex to Announce Fourth Quarter 2008 Financial Results on February 11, 2009
9. Cambrex Reports Fourth Quarter and Full Year 2008 Results
10. Amarin Regains Compliance With Nasdaq Listing Requirements
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Fla. (PRWEB) , ... August 19, 2017 , ... ... Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain management ... anesthesiology, a focus on the treatment of migraine headaches, and significant experience in ...
(Date:8/18/2017)... ... August 18, 2017 ... ... For Immediate Release                Contact: Julian Teixeira, August 18, 2017                    202-478-8564 / ... Relationship Advice from their Fathers , Contrary to a ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, ... to communities in North-Central West Virginia, is embarking on a cooperative charity effort ... the area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & ... serves residential and commercial clients in the greater Houston region, is helping locally ... for the fight against cancer. , Founded by Tony and Amber Bender after ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Inc., the creator of the drug Truveta for the treatment ... IPO. The United States spends approximately ... prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... is the fact that Americans spent $42 billion on anxiety medications last ...
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: